Please login to the form below

Not currently logged in


This page shows the latest leukemia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Amgen has gained EU marketing approval to extend use of Blincyto (blinatumomab) in children with acute lymphoblastic leukemia (ALL), putting it into direct competition with Novartis’new CAR-T treatment Kymriah.

Latest news

More from news
Approximately 5 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There are also global direct-to-patient access programmes for Gleevec and Tasigna, life-saving therapies for chronic myeloid leukemia and gastrointestinal stromal tumours.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...